수막염균 백신 시장 규모, 점유율, 성장 및 세계 산업 분석 : 유형별, 용도별, 지역별 인사이트 및 예측(2024-2032년)

Growth Factors of meningococcal vaccines Market

The global meningococcal vaccines market continues to advance significantly, driven by rising cases of vaccine-preventable meningococcal diseases and increasing global immunization efforts. According to the 2024 report, the meningococcal vaccines market size reached USD 3.54 billion in 2024. The market is projected to increase to USD 3.81 billion in 2025 and rise further to USD 7.34 billion by 2032, expanding at a CAGR of 9.8% between 2025 and 2032. In 2024, North America dominated the global market with a 57.34% share, indicating strong vaccination coverage and large-scale adoption of approved vaccines.

Meningococcal diseases-including meningitis, sepsis, and pneumonia-are caused by Neisseria meningitidis. Although 12 serogroups exist, six (A, B, C, W, X, and Y) are responsible for major epidemics. Bacterial meningitis remains life-threatening, often causing severe neurological damage or death if not treated promptly. The rising burden of meningococcal infections, coupled with increasing awareness and global collaborations for vaccine development, continues to drive substantial market growth. For example, in April 2024, the Serum Institute of India partnered with the University of Oxford to develop a chimeric protein-based Men-B vaccine, expanding future vaccine possibilities.

Market Dynamics

Drivers

The increasing number of bacterial meningococcal infections is significantly boosting vaccine demand. WHO reports indicate that 1 in 6 bacterial meningitis patients die, and 1 in 5 suffer long-term complications such as brain damage or amputations. In 2023, the U.S. reported 438 cases of meningococcal disease, the highest incidence in a decade, highlighting the urgent need for immunization programs. Such rising disease patterns support fast-growing demand for both routine and emergency meningococcal vaccinations.

Restraints

A key market restraint is the high cost of conjugate vaccines. Manufacturing complexity, multi-component formulations, and cold-chain storage requirements contribute to elevated pricing. According to the CDC Vaccine Price List (June 2025), Penbraya costs USD 230.75 per vial, while MenQuadfi costs USD 171.97 for a 10-pack dose-prices that may slow adoption in low-income regions without insurance coverage.

Opportunities

Global vaccination initiatives present strong growth opportunities. WHO's "Defeating Meningitis by 2030" roadmap emphasizes expanded immunization programs using affordable vaccines, including Men5CV. In April 2025, WHO released the first global guidelines for meningitis diagnosis, treatment, and long-term care, significantly strengthening global preparedness.

Challenges

Cold-chain logistics remain a major challenge, especially in low-resource settings. As per the 2023 U.K. Health Security Agency report, vaccine wastage due to avoidable reasons cost USD 3.3 million, while unavoidable cold-chain failures cost USD 3.7 million. Such losses increase pressure on public health budgets.

Market Segmentation Highlights

Recombinant/conjugate/subunit vaccines dominated in 2024, supported by widespread availability of conjugate vaccines and new product approvals such as GSK's single-vial Menveo in November 2024. The MenACWY segment led by type due to broad, school-based immunization recommendations across multiple countries.

Pediatric vaccines generated the highest demand in 2024, strengthened by expansions such as Sanofi's MenQuadfi pediatric indication (May 2025) for infants aged 6 weeks to 23 months.

Government suppliers represented the leading distribution channel in 2024 because of large-scale national immunization programs. For example, Nigeria became the first country to introduce Men5CV in April 2024, supported by Gavi.

Regional Outlook

North America remained the dominant region with a 2024 market size of USD 2.03 billion, driven by rising IMD cases and strong public health infrastructure. In June 2024, Toronto Public Health reported 13 IMD cases, the highest since 2002.

Asia Pacific held the second-largest share in 2024 and is projected to grow fastest through 2032, supported by WHO-prequalified vaccines such as Serum Institute's MenFive in July 2023. Europe continues to benefit from high routine immunization coverage, including 91% MenB vaccination-rate among children in England in 2022-23.

Latin America and Middle East & Africa remain growing markets, especially in the meningitis belt, where incidence rose from 0.05 to 0.18 per 100,000 between 2021 and 2023.

Conclusion

With global market value rising from USD 3.54 billion in 2024 to USD 7.34 billion by 2032, the meningococcal vaccines market is set for substantial long-term expansion. Strong R&D efforts, supportive government initiatives, and increased disease awareness will continue to drive growth through 2032.

Segmentation By Technology

• Recombinant/Conjugate/Subunit
• Inactivated
• Others

By Type

• MenACWY Vaccines
• MenB Vaccines
• MenABCWY Vaccines
• Others

By Age Group

• Pediatric
• Adults

By Distribution Channel

• Hospital & Retail Pharmacies
• Government Suppliers
• Others

By Geography

• North America (By Technology, Type, Age Group, Distribution Channel, and Country)
  • U.S.
  • Canada
• Europe (By Technology, Type, Age Group, Distribution Channel, and Country/Sub-region)
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Technology, Type, Age Group, Distribution Channel, and Country/Sub-region)
  • Japan
  • China
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Technology, Type, Age Group, Distribution Channel, and Country/Sub-region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Technology, Type, Age Group, Distribution Channel, and Country/Sub-region)
  • GCC
  • South Africa
• Rest of the Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Regulatory Scenarios, By Key Countries/Regions
• 4.2. Vaccination Coverage- By Key Countries/ Regions
• 4.3. Government Immunization Programs for Meningitis, By Key Countries/ Regions
• 4.4. Technological Advancements in Meningococcal Vaccines Market
• 4.5. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, etc.)

5. Global Meningococcal Vaccines Market Analysis, Insights and Forecast, 2019-2032

• 5.1. Market Analysis, Insights and Forecast - By Technology
  • 5.1.1. Recombinant/Conjugate/Subunit
  • 5.1.2. Inactivated
  • 5.1.3. Others
• 5.2. Market Analysis, Insights and Forecast - By Type
  • 5.2.1. MenACWY Vaccines
  • 5.2.2. MenB Vaccines
  • 5.2.3. MenABCWY Vaccines
  • 5.2.4. Others
• 5.3. Market Analysis, Insights and Forecast - By Age Group
  • 5.3.1. Pediatric
  • 5.3.2. Adults
• 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.4.1. Hospital & Retail Pharmacies
  • 5.4.2. Government Suppliers
  • 5.4.3. Others
• 5.5. Market Analysis, Insights and Forecast - Region
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Latin America
  • 5.5.5. Middle East & Africa

6. North America Meningococcal Vaccines Market Analysis, Insights and Forecast, 2019-2032

• 6.1. Market Analysis, Insights and Forecast - By Technology
  • 6.1.1. Recombinant/Conjugate/Subunit
  • 6.1.2. Inactivated
  • 6.1.3. Others
• 6.2. Market Analysis, Insights and Forecast - By Type
  • 6.2.1. MenACWY Vaccines
  • 6.2.2. MenB Vaccines
  • 6.2.3. MenABCWY Vaccines
  • 6.2.4. Others
• 6.3. Market Analysis, Insights and Forecast - By Age Group
  • 6.3.1. Pediatric
  • 6.3.2. Adults
• 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.4.1. Hospital & Retail Pharmacies
  • 6.4.2. Government Suppliers
  • 6.4.3. Others
• 6.5. Market Analysis, Insights and Forecast - By Country
  • 6.5.1. U.S.
  • 6.5.2. Canada

7. Europe Meningococcal Vaccines Market Analysis, Insights and Forecast, 2019-2032

• 7.1. Market Analysis, Insights and Forecast - By Technology
  • 7.1.1. Recombinant/Conjugate/Subunit
  • 7.1.2. Inactivated
  • 7.1.3. Others
• 7.2. Market Analysis, Insights and Forecast - By Type
  • 7.2.1. MenACWY Vaccines
  • 7.2.2. MenB Vaccines
  • 7.2.3. MenABCWY Vaccines
  • 7.2.4. Others
• 7.3. Market Analysis, Insights and Forecast - By Age Group
  • 7.3.1. Pediatric
  • 7.3.2. Adults
• 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.4.1. Hospital & Retail Pharmacies
  • 7.4.2. Government Suppliers
  • 7.4.3. Others
• 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 7.5.1. Germany
  • 7.5.2. U.K.
  • 7.5.3. France
  • 7.5.4. Italy
  • 7.5.5. Spain
  • 7.5.6. Scandinavia
  • 7.5.7. Rest of Europe

8. Asia Pacific Meningococcal Vaccines Market Analysis, Insights and Forecast, 2019-2032

• 8.1. Market Analysis, Insights and Forecast - By Technology
  • 8.1.1. Recombinant/Conjugate/Subunit
  • 8.1.2. Inactivated
  • 8.1.3. Others
• 8.2. Market Analysis, Insights and Forecast - By Type
  • 8.2.1. MenACWY Vaccines
  • 8.2.2. MenB Vaccines
  • 8.2.3. MenABCWY Vaccines
  • 8.2.4. Others
• 8.3. Market Analysis, Insights and Forecast - By Age Group
  • 8.3.1. Pediatric
  • 8.3.2. Adults
• 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.4.1. Hospital & Retail Pharmacies
  • 8.4.2. Government Suppliers
  • 8.4.3. Others
• 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 8.5.1. China
  • 8.5.2. Japan
  • 8.5.3. India
  • 8.5.4. Australia
  • 8.5.5. Southeast Asia
  • 8.5.6. Rest of Asia Pacific

9. Latin America Meningococcal Vaccines Market Analysis, Insights and Forecast, 2019-2032

• 9.1. Market Analysis, Insights and Forecast - By Technology
  • 9.1.1. Recombinant/Conjugate/Subunit
  • 9.1.2. Inactivated
  • 9.1.3. Others
• 9.2. Market Analysis, Insights and Forecast - By Type
  • 9.2.1. MenACWY Vaccines
  • 9.2.2. MenB Vaccines
  • 9.2.3. MenABCWY Vaccines
  • 9.2.4. Others
• 9.3. Market Analysis, Insights and Forecast - By Age Group
  • 9.3.1. Pediatric
  • 9.3.2. Adults
• 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.4.1. Hospital & Retail Pharmacies
  • 9.4.2. Government Suppliers
  • 9.4.3. Others
• 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 9.5.1. Brazil
  • 9.5.2. Mexico
  • 9.5.3. Rest of Latin America

10. Middle East & Africa Meningococcal Vaccines Market Analysis, Insights and Forecast, 2019-2032

• 10.1. Market Analysis, Insights and Forecast - By Technology
  • 10.1.1. Recombinant/Conjugate/Subunit
  • 10.1.2. Inactivated
  • 10.1.3. Others
• 10.2. Market Analysis, Insights and Forecast - By Type
  • 10.2.1. MenACWY Vaccines
  • 10.2.2. MenB Vaccines
  • 10.2.3. MenABCWY Vaccines
  • 10.2.4. Others
• 10.3. Market Analysis, Insights and Forecast - By Age Group
  • 10.3.1. Pediatric
  • 10.3.2. Adults
• 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 10.4.1. Hospital & Retail Pharmacies
  • 10.4.2. Government Suppliers
  • 10.4.3. Others
• 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 10.5.1. GCC
  • 10.5.2. South Africa
  • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2024)
• 11.2. Company Profiles
  • 11.2.1. GSK plc
    • 11.2.1.1. Overview
    • 11.2.1.2. Products & services
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. Financials (Based on Availability)
  • 11.2.2. Sanofi
    • 11.2.2.1. Overview
    • 11.2.2.2. Products & services
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. Financials (Based on Availability)
  • 11.2.3. Merck & Co., Inc.
    • 11.2.3.1. Overview
    • 11.2.3.2. Products & services
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. Financials (Based on Availability)
  • 11.2.4. Serum Institute of India Pvt. Ltd.
    • 11.2.4.1. Overview
    • 11.2.4.2. Products & services
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. Financials (Based on Availability)
  • 11.2.5. Novartis AG
    • 11.2.5.1. Overview
    • 11.2.5.2. Products & services
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. Financials (Based on Availability)
  • 11.2.6. Walvax Biotechnology Co., Ltd.
    • 11.2.6.1. Overview
    • 11.2.6.2. Products & services
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. Financials (Based on Availability)
  • 11.2.7. Hualan Biological Vaccine Inc.
    • 11.2.7.1. Overview
    • 11.2.7.2. Products & services
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. Financials (Based on Availability)
  • 11.2.8. Bio Farma
    • 11.2.8.1. Overview
    • 11.2.8.2. Products & services
    • 11.2.8.3. SWOT Analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. Financials (Based on Availability)
  • 11.2.9. BioNet-Asia.
    • 11.2.9.1. Overview
    • 11.2.9.2. Products & services
    • 11.2.9.3. SWOT Analysis
    • 11.2.9.4. Recent Developments
    • 11.2.9.5. Strategies
    • 11.2.9.6. Financials (Based on Availability)